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Highlights 
*Disease relevant innate immune monocyte markers are altered in Parkinson’s disease 
*The monocyte marker changes are accompanied by elevated serum bacterial endotoxin 
*These findings are most pronounced in Parkinson’s cases at higher dementia risk 

















The innate immune system is implicated in Parkinson’s disease (PD), but peripheral in-vivo 
clinical evidence of the components and driving mechanisms involved and their relationship 
with clinical heterogeneity and progression to dementia remain poorly explored.  
 
We examined changes in peripheral innate immune-related markers in PD cases (n=41) 
stratified according to risk of developing early dementia. ‘Higher Risk’(HR) (n=23) and 
‘Lower Risk’ (LR) (n=18) groups were defined according to neuropsychological predictors and 
MAPT H1/H2 genotype, and compared to age, gender and genotype-matched controls. 
Monocyte subsets and expression of key surface markers were measured using flow cytometry. 
Serum markers including alpha-synuclein, inflammasome-related caspase-1 and bacterial 
translocation-related endotoxin were measured using quantitative immuno-based assays. 
Specific markers were further investigated using monocyte assays and validated in plasma 
samples from a larger incident PD cohort (n=95).  
 
We found that classical monocyte frequency was elevated in PD cases compared to controls, 
driven predominantly by the HR group, in whom Toll-Like Receptor (TLR)4+ monocytes and 
monocyte Triggering Receptor Expressed on Myeloid cells-2 (TREM2) expression were also 
increased. Monocyte Human Leukocyte Antigen (HLA)-DR expression correlated with clinical 
variables, with lower levels associated with worse cognitive/motor performance. Notably, 
monocyte changes were accompanied by elevated serum bacterial endotoxin, again 
predominantly in the HR group.                                                                                                                       
Serum alpha-synuclein and inflammasome-related caspase-1 were decreased in PD cases 
compared to controls regardless of group, with decreased monocyte alpha-synuclein secretion 
in HR cases. Further, alpha-synuclein and caspase-1 correlated positively in serum and 
monocyte lysates, and in plasma from the larger cohort, though no associations were seen with 
baseline or 36-month longitudinal clinical data.  
Principal Components Analysis of all monocyte and significant serum markers indicated 3 
major components. Component 1 (alpha-synuclein, caspase-1, TLR2+ monocytes) 
differentiated PD cases and controls in both groups, while Component 2 (endotoxin, monocyte 
TREM2, alpha-synuclein) did so predominantly in the HR group. Component 3 (classical 
monocytes, alpha-synuclein) also differentiated cases and controls overall in both groups.  
 
These findings demonstrate that systemic innate immune changes are present in PD and are 
greatest in those at higher risk of rapid progression to dementia. Markers associated with PD 
per-se (alpha-synuclein, caspase-1), differ from those related to cognitive progression and 
clinical heterogeneity (endotoxin, TREM2, TLR4, classical monocytes, HLA-DR), with 
mechanistic and therapeutic implications.  Alpha-synuclein and caspase-1 are associated, 
suggesting inflammasome involvement common to all PD, while bacterial translocation 
associated changes may contribute towards progression to Parkinson’s dementia. Additionally, 
HLA-DR-associated variations in antigen presentation/clearance may modulate existing 
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Parkinson’s disease (PD) is clinically and pathologically heterogeneous (Rajput et al., 
2009)(Kehagia et al., 2010)(Greenland et al., 2019). Clinical and genetic factors at diagnosis 
are known to predict the rate of progression to dementia, which affects around 50% of patients 
by 10 years (Williams-Gray et al., 2013). However, the biological drivers of heterogeneity in 
progression rates are not fully understood, and are likely to be complex, arising from 
interactions between genetic and environmental risk factors acting at multiple levels.  
 
Mounting evidence from several fields has implicated involvement of the immune system in 
PD, however the precise components and mechanisms involved and their relationships with 
clinical heterogeneity and progression to dementia remain poorly understood. Genetic studies 
have indicated associations between immune related gene variants and PD risk (e.g. Human 
Leukocyte Antigen-DR (HLA-DR), Triggering Receptor Expressed on Myeloid cells-2 
(TREM2), Toll-like receptor 4 (TLR4) (Nalls et a l., 2011)(Hamza et al., 2010)(Rayaprolu et 
al., 2013)(Zhao et al., 2015)), while established PD related genes such as Leucine Rich Repeat 
Kinase 2 (LRRK2) have demonstrated involvement in the innate immune system (H. Lee et 
al., 2017) and immune-mediated conditions such as inflammatory bowel disease (Dzamko, 
2017). Epidemiological studies have suggested a decreased risk of PD with anti-inflammatory 
and immunosuppressant drug use (X. Gao et al., 2011)(Ju et al., 2019)(Racette et al., 2018) and 
increased risk with immune-related conditions such as autoimmune diseases (Chang et al., 
2018)  and infections (Pakpoor et al., 2017)(Vlajinac et al., 2013). Animal models have also 
suggested involvement of the immune system in driving PD pathology, with systemic 
lipopolysaccharide (LPS) administration (H.-M. Gao et al., 2011) worsening alpha-synuclein 
pathology. Mice lacking mature T and B lymphocytes (Brochard et al., 2009) have decreased 
cell loss in a toxin-based model of PD and Central Nervous System (CNS) infiltration of C-C 
motif chemokine Receptor2+ (CCR2+) monocytes (Harms et al., 2017) has also been shown 
to influence disease pathology and expression.  
 
In the human PD brain, microglial activation has been demonstrated, both at post mortem 
(McGeer and McGeer, 2008) and in-vivo using Positron Emission Tomography (PET) 
neuroimaging (Gerhard et al., 2006). Several studies have also identified peripheral immune 
changes in PD patients, including increases in serum and secreted cytokines (e.g. Tumour 
Necrosis Factor (TNF)-α, Interleukin (IL)-1β, IL-2 and IL-10) (Williams-Gray et al., 
2016)(Qin et al., 2016)(Sulzer et al., 2017), and associations between a more ‘pro-
inflammatory’ cytokine profile at diagnosis and faster motor progression and impaired 
cognition over 3 years follow-up (Williams-Gray et al., 2016).   
 
Many immune components are likely to play a role, and studies have demonstrated changes in 
adaptive immune factors such as variations in T lymphocyte subtypes and function (Baba et 
al., 2005)(Cen et al., 2017)(Sulzer et al., 2017)(Williams-Gray et al., 2018), decreased B 
lymphocytes (Stevens et al., 2012) and alterations in serum antibody levels (Scott et al., 2018) 
in PD. However, many of the key genetic links (HLA-DR, TREM2, TLR4) and imaging 
evidence have implicated specific involvement of the ‘innate’ immune system. In addition to 
central microglial activation, innate immune abnormalities have been seen in the cerebrospinal 
fluid (Schröder et al., 2018) and the periphery, with changes in monocyte subtype and marker 
expression (Grozdanov et al., 2014)(Funk et al., 2013). Studies have specifically found 
increased numbers of classical monocytes, increased monocyte CCR2, TLR2 and TLR4 
expression (Funk et al., 2013)(Drouin-Ouellet et al., 2015), enhanced phagocytosis (Grozdanov 
et al., 2014)(Gardai et al., 2013)(Wijeyekoon et al., 2018) and reduced viability in culture 
(Nissen et al., 2019).  
 
There is also increasing evidence that alpha-synuclein, the key pathological protein in PD, can 
be influenced by, and exert influence on, innate immune pathways and related microbial 
factors. Microbial involvement has been shown to influence disease pathology (Sampson et al., 
2016) and alpha-synuclein itself may be produced, altered or trafficked in response to 
microbial/immune related challenges including bacterial endotoxin (Forsyth et al., 
2011)(Stolzenberg et al., 2017)(Wang et al., 2016). Caspase-1, a key component of the innate 
immune inflammasome pathway (which is activated by a range of damage and pathogen 
associated molecular patterns (DAMPs/PAMPs)), can cleave alpha-synuclein and make it more 
aggregable, while Lewy bodies have been found to stain for caspase-1 together with alpha-
synuclein (Wang et al., 2016). Forms of alpha-synuclein are also capable of activating the TLR 
and inflammasome pathways, leading to further cytokine production and inflammation 
(Codolo et al., 2013)(Gustot et al., 2015)(Kim et al., 2013)(White et al., 2018)(Grozdanov et 
al., 2019).  
 
Although these lines of evidence implicate the innate immune system in PD, there has been 
limited characterisation of systemic innate immune and associated factors and their relevance 
to clinical heterogeneity and disease progression rate, in clinical PD cases. Consequently, we 
sought to pursue such an investigation, by characterising relevant peripheral innate immune 
components in the blood of a cohort of early-moderate stage PD cases stratified around risk for 
early dementia and paired matched controls without neurological disease. We also investigated 
blood samples for the presence of factors implicated in driving the innate immune changes in 
PD, including alpha-synuclein and bacterial endotoxin. We used a data driven approach to 
explore the relationships between these factors and innate immune changes and assessed links 
with disease status and dementia risk.  
 
2. Materials and Methods 
2.1 Participants 
Ethical approval was obtained from the Cambridgeshire Research Ethics Committee and 
written consent was obtained from participants in compliance with the Declaration of Helsinki. 
Parkinson’s cases were recruited from the PD Research Clinic at the John van Geest Centre for 
Brain Repair, University of Cambridge.  
 
Inclusion criteria comprised satisfying UK Brain Bank Criteria for Parkinson’s disease, age 
55-80 and Hoehn and Yahr (HY) stage ≤ 2.  
In order to classify patients a priori according to their risk of progression to dementia, the study 
utilised factors previously identified from the CamPaIGN longitudinal cohort study (semantic 
fluency score <20, impaired pentagon copying and H1/H1 MAPT haplotype)(Williams-Gray 
et al., 2009)(Williams-Gray et al., 2013). Each factor contributes significantly to increased 
dementia risk at 10 years, with a hazard ratio of 3.05 for semantic fluency <20, 2.55 for 
impaired pentagon copying and 3.08 for Microtubule Associated Protein Tau (MAPT) 
H1/H1(Williams-Gray et al., 2013).  
The ‘Higher Dementia Risk’ (HR) group had at least one of these factors at diagnosis, while 
the ‘Lower Dementia Risk’ (LR) group had none.  
 
Age, gender and MAPT-genotype matched controls, with no history of neurological disease, 
self-reported memory problems or depression were recruited via the Cambridge 
Bioresource(http://www.cambridgebioresource.org.uk).  
 
Exclusion criteria for all participants consisted of the presence of-: another neurodegenerative, 
chronic inflammatory or autoimmune disorder, current clinically significant infection, surgery 
within last month, vaccinations in the last 3 weeks, use of steroids (within last 3 months), 
aspirin >75mg or ibuprofen/nonsteroidal anti-inflammatory drugs (within 2 weeks) or long-
term immunosuppressant drugs (within 1 year).   
 
2.2 Clinical data acquisition and sample collection    
Participants attended for three visits at monthly intervals. Data gathered included demographic 
data, medical and drug history and comorbidity status (Cumulative Illness Rating Scale 
(CIRS)(Parmelee et al., 1995)). Verbal screening for inter-current infections was performed to 
avoid sampling during periods of illness. Clinical assessments included the Movement 
Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), HY scale, 
Addenbrooke’s Cognitive Examination-Revised (ACE-R), semantic fluency (animals in 90s) 
and pentagon copying.   
Venous blood (up to 50ml) was sampled at each visit and used for serum extraction and/or 
Peripheral Blood Mononuclear Cell (PBMC) isolation and subsequent ex-vivo 
immunocytochemistry/flow cytometry or CD14+ cell separation. All samples were collected 
between 9.00 and 11.00am, with no imposed medication changes. PD/control samples paired 








2.3 Sample Processing 
2.3.1 PBMC isolation, Immunocytochemistry and Flow Cytometry 
PBMCs were extracted using the standard Ficoll gradient method and subjected to 
immunocytochemistry and flow cytometry as previously described (Appendix A) (Wijeyekoon 
et al., 2018), to measure key monocyte cell surface markers.  
The antibody panel used for flow cytometry consisted of CD14 – APC-H7, CD16 – PerCP-
Cy5.5, HLA-DR – BV605, TREM2 –APC, TLR2 – PE, TLR4 – BV421 (Table A.1). 
Monocytes were gated and analysed as described in the literature (Ziegler-Heitbrock and Hofer, 
2013)(Fig. 1A) and as detailed in Appendix A.  
 
2.3.2 Serum sample processing and assays 
Blood samples for serum collection were left to clot for 15 minutes and centrifuged at 2000rpm 
for 15 minutes at room temperature. The separated serum was stored in 200-400 µl aliquots, 
frozen at -80°C and thawed before use. The following assays were performed (see Appendix 
A for further details).  
 
Mesoscale Discovery (MSD) platform electrochemiluminescence assays 
Samples from each of the 3 visits were processed in duplicate according to the manufacturer’s 
instructions for the MSD V-Plex 10-spot Pro-inflammatory panel 1 assay (Interferon(IFN)-γ, 
IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and TNFα; 1:2 dilution; 50ul per well); 
MSD V-Plex Human C-Reactive Protein (CRP) assay (1:1000 dilution; 25ul per well); MSD 
Human Alpha-Synuclein Assay (1:10 dilution; 25ul per well).  
Readings were obtained using the MSD SECTOR Imager. Data was exported and analysed 
using the MSD Discovery Workbench software.  
 
Additional assays -: Caspase-1, soluble CD14, soluble TREM2 and bacterial endotoxin 
Additional markers were measured from remaining serum aliquots and included-: caspase-1 
(Wang et al., 2016)(Codolo et al., 2013); bacterial endotoxin (a primary ligand for TLR4) and 
soluble CD14, as markers of microbial translocation (Morris et al., 2015)(Kelesidis et al., 
2012); and soluble TREM2, as an indicator of TREM2 shedding (Feuerbach et al., 2017).  
 
Samples were analysed in duplicate using ELISA assays for caspase-1(R and D Systems) (2:3 
dilution), soluble TREM2(Cloud-Clone Corp.)(1:2 dilution), and soluble CD14(R and D 
systems) (1:800 dilution), following the manufacturer’s instructions (Appendix A).  
Serum endotoxin was measured using the Pierce Limulus Amoebocyte Lysate (LAL) 
Chromogenic Endotoxin Quantitation Kit (Thermo Scientific) (40 samples) and the LAL 
Chromogenic Endpoint Assay (Hycult Biotech) (36 samples), due to supplier shortages of the 
former during the course of the study. Samples from PD and control pairs were analysed using 
the same plate and kit. The results from both batches covered similar ranges (Thermo Scientific 
kit – 0.46 – 6.32 EU/ml; Hycult Biotech kit – 0.46 – 5.00 EU/ml). All samples were assayed 
in duplicate according to the manufacturer’s instructions, with 1:50 dilution.  
 
2.3.3 Monocyte separation  
Monocytes were separated using MACS® CD14 magnetic beads (Miltenyi Biotec) as per the 





2.3.4 Fluorescent alpha-synuclein endocytosis assays 
Monocyte uptake of recombinant human alpha-synuclein (1-140) HiLyteTM Fluor 488 
(Anaspec) was assessed in standard medium (clear Roswell Park Memorial Institute (RPMI) 
culture medium and 10% Foetal Calf Serum (FCS)), and in autologous serum (Appendix A). 
Titration and time course experiments were performed prior to study commencement, to 
optimise concentrations and end time points. Final assays were run using 10,000ng/ml of alpha-
synuclein for an incubation period of 90 minutes. Alpha-synuclein uptake was assessed and 
quantified using flow cytometry. Representative post-uptake monocyte samples were used for 
imaging using fluorescence microscopy.   
 
2.3.5 Monocyte alpha-synuclein and caspase-1 secretion assays 
Separated monocytes were cultured in RPMI and 10% FCS under standard conditions at a 
concentration of 1x106 cells per ml per well, with and without LPS (1ng/ml). Paired PD and 
control cultures, with and without LPS, were performed in parallel. The supernatant was 
collected at 24h, aliquoted and stored at -80ºC.  
Supernatants were analysed for alpha-synuclein and caspase-1 according to the manufacturer’s 
instructions as detailed above and in Appendix A. Supernatants were diluted 1:10 for alpha-
synuclein and 2:3 for caspase-1 in the appropriate buffers and were assayed in duplicate.  
 
2.3.6 Monocyte Lysates 
Monocytes were lysed in homogenisation solution (Appendix A), and their total protein 
concentration was measured using a Bicinchoninic acid (BCA) assay (Appendix A). Alpha-
synuclein and caspase-1 levels were measured in monocyte lysates using the assays and 
dilutions described above. Western blots for alpha-synuclein and caspase-1 were performed on 
the monocyte lysates, with β-actin as loading control (Appendix A).   
 
2.4 Statistical analysis 
Data was analysed using IBM SPSS version 25 or GraphPad Prism 7. Experimental outliers >3 
standard deviations (SD) above or below the mean were excluded and normality was assessed 
using the Shapiro-Wilk test prior to analysis. Due to the paired experimental methodology, 
group comparisons were performed for PD cases overall and within each a priori determined 
risk group versus paired controls using paired two-tailed t-tests (parametric) or Wilcoxon 
matched-pairs tests (non-parametric) as appropriate. Bonferroni correction for multiple testing 
was used across each assay category (e.g. monocyte subtypes, monocyte surface expression 
markers, all serum assays). All monocyte markers and serum markers with a PD-Control 
uncorrected significant difference of p<0.05 were included in a Principal Components Analysis 
(PCA).  
Relationships between monocyte/serum markers and clinical variables (MDS-UPDRS motor, 
ACE-R and semantic fluency scores) were assessed using bivariate correlation analysis. 
Markers reaching significance (p<0.05) were included in multiple regression analyses for each 
clinical variable with appropriate confounders. Correlations between PCA component scores 
and clinical variables were compared using similar methods.  
 
2.5 Plasma markers and disease progression 
Stored baseline plasma samples were available for another cohort of 93 patients (Incidence of 
Cognitive Impairment in Cohorts with Longitudinal Evaluation in Parkinson's Disease 
(ICICLE‐PD) Cambridge cohort) who were newly diagnosed with PD and recruited between 
2009 and 2011 from community/outpatient clinics in Cambridge, United Kingdom. Details of 
recruitment, assessment and follow up of the patients have been previously published (Yarnall 
et al., 2014). Subjects were assessed clinically as previously described (Williams-Gray et al., 
2016), at baseline, 18 and 36 months.  
Venous blood samples (EDTA tubes) were obtained at baseline entry to the study and plasma 
extracted by centrifugation (2000rpm for 15 minutes), with storage at -80ºC. On use, plasma 
was thawed and processed for alpha-synuclein and caspase-1(1:50 dilution)(Appendix A). 
Relationships between baseline plasma markers and longitudinal clinical progression were 
analysed using simple bivariate correlation analyses. Significant correlations were further 
examined using multiple regression analyses with relevant confounders. 
 
2.6 Data availability 
Data related to the findings of this study will be available from the corresponding author, upon 



















41 Parkinson’s disease cases and 41 paired matched controls were recruited (23 pairs HR group 




Table 1 – Demographic details of participant groups (Mean ± Standard Deviation). *p<0.05. 
MDS-UPDRS – Movement Disorder Society Unified Parkinson’s Disease Rating Scale; ACE-
R – Addenbrooke’s Cognitive Examination- Revised; CIRS – Cumulative Illness Rating Scale.  




Higher Risk (HR) Group 
 
 
Lower Risk (LR) Group 














Number (n) 23 23  18 18   
Age (years) 70.13± 5.96 
69.43± 
5.40 










4.26 ± 1.09 
 














ACE-R score 89.96± 9.94 96.88±2.31 0.008* 
CIRS 
Total Score 
4.30 ± 2.05 5.39 ± 2.99 0.177 
3.2 Monocyte markers 
There were no significant differences in total monocytes (as a percentage of PBMCs) between 
PD and paired controls, overall (t(40)=0.5446, p=0.5891) nor in both risk groups (Fig.1B). PD 
cases had a statistically significant (withstanding Bonferroni correction for multiple testing) 
higher proportion of classical monocytes (W=-445, p=0.0014), with trends (uncorrected 
significance) towards correspondingly lower intermediate (t(37)=2.334, p=0.0251) and non-
classical (W=278, p=0.0433) monocytes, compared to paired controls (Fig.1C-E). Risk group 
analysis revealed a trend towards higher classical monocyte percentages in the HR PD group 
(W= -141, p=0.0127) compared to paired controls, but not the LR group (Fig.1C). 
 
TLR4+ monocytes constituted a higher percentage in PD compared to controls (W= -204, 
p=0.0128), with statistical significance in the HR PD group (W= -124, p=0.0004). The 
percentage of TLR2+ monocytes was also significantly higher in all PD cases (W= -347, 
p=0.0078)compared to controls and within the HR PD group (W= -134, p=0.0107) (Fig.2A-
D).   
 
Monocyte TREM2 and HLA-DR measures did not differ between PD cases and controls. 
However, HR group PD cases had significantly higher monocyte TREM2 expression 
(t(19)=2.977, p=0.0077) compared to paired controls and a trend towards a higher percentage 
of TREM2+ monocytes (t(20)=2.216, p=0.0385), while LR PD cases demonstrated a trend 
towards a lower percentage of TREM2+ monocytes (t(17)=2.457, p=0.0250) (Fig.2E-H).  
 
Additional analyses performed on the Classical monocyte sub-population indicated similar 
patterns of changes to Total monocytes in all measured markers, but with decreased 
significance overall, possibly due to smaller cell numbers within the subpopulation (Appendix 




Figure 1 – Monocyte subtypes  
(A) - Flow cytometry gating strategy for monocytes and monocyte subtypes Singlets are 
identified by plotting Forward Scatter-Area (FSC-A) versus Forward Scatter-Width (FSC-W) 
and excluding cells with multiples of a single width size. Monocyte are broadly distinguished 
using tight gates based on FSC-A (size) and Side Scatter-Area (SSC-A) (granularity/internal 
complexity). Monocyte subtypes are distinguished based on CD14 and CD16 expression –
Classical (CD14 high, CD16 negative); Intermediate (CD14 high, CD16 positive); Non-
Classical (CD14 low, CD16 high).  
(B) - Total monocytes (as a percentage of PBMCs) in all patients and controls; overall and 
within dementia risk groups. (Parkinson’s disease=red; Controls=yellow). 
(C),(D),(E)-Monocyte Subtypes. (C) Classical, (D) Intermediate and (E) Non-Classical 
monocytes (as percentage of total monocytes) in Parkinson’s disease patients and controls; 
overall and within dementia risk groups. (Parkinson’s disease=red; Controls=yellow). 







Figure 2 – Monocyte surface markers 
Total monocyte marker expression in Parkinson’s disease cases versus paired controls; overall 
and within risk groups.  Graphs showing total monocyte MFI (Median Fluorescence Intensity) 
ratios (Test/Isotype) ((A), (C), (E), (G)) and percentage monocytes positive ((B), (D), (F), (H)). 
(Parkinson’s disease=red; Controls=yellow). **significance withstood Bonferroni correction 
for multiple testing within the relevant category.  
 
3.3 Monocyte markers and clinical variables 
Monocyte HLA-DR surface expression levels correlated with better cognitive function (higher 
ACE-R (r=0.402, p=0.015) and semantic fluency (r=0.440, p=0.006)) and motor function 
(lower UPDRS motor score (r=-0.398, p=0.016)). There were no correlations with levodopa 
equivalent dose, suggesting the associations were unlikely to be medication driven (Fig.3). 
There were no significant correlations between clinical scores and other monocyte marker 
measures (data not shown). 
Multivariate regression analysis with the UPDRS motor score, semantic fluency or ACE-R 
scores as the dependent variables, and age, disease duration, levodopa equivalent dose and 
CIRS comorbidity score as potential confounders, confirmed the relationships with total 




Figure 3 – Monocyte HLA-DR expression and clinical data 
Relationships between Total Monocyte HLA-DR expression (Test/Isotype MFI Ratio) and 
clinical data - (A) Semantic Fluency. (B) MDS-UPDRS III motor score. (C) ACE-R score. (D) 








3.4 Serum markers  
Serum alpha-synuclein concentration was significantly lower in PD cases compared to 
controls, regardless of risk group (Overall W=810, p<0.0001; HR W=276, p<0.0001; LR 
W=147, p<0.0001)(Fig.4A).  
Serum caspase-1 was also significantly lower in PD compared to controls, regardless of risk 
group (Overall W=596, p<0.0001; HR W=139, p=0.0013; LR W=161, p<0.0001) (Fig.4B).  
 
Serum endotoxin was higher in PD compared to controls (W=-287, p=0.0231), with a non-
significant trend in the HR group (W=-79, p=0.0898) (Fig.4C).  
Serum IL-2 and IFN-γ displayed trends towards decrease in the HR-PD group, but there were 
no statistically significant case-control differences in the serum concentrations of measured 
cytokines, CRP, soluble CD14 or soluble TREM2 in patients compared to controls (Tables A.3 
and A.4; Fig.4D,E).  
 
 For both monocyte markers and serum variables, gender-stratified paired comparisons 
indicated overall similar trends in all markers within both genders, though significance was 












Figure 4 – Serum markers and Principal Components Analysis  
(A)-(E) - Concentrations of serum (A) alpha-synuclein, (B) caspase-1, (C) endotoxin, (D) 
soluble CD14 and (E) soluble TREM2 in Parkinson’s disease patients and controls and within 
Parkinson’s dementia risk groups. (Patients=red; Controls=yellow). **significance withstood 
Bonferroni correction for multiple testing within the relevant category. 
(F)-(H) - Summary of Principal Components Analysis (PCA) component score comparisons 
between all Parkinson’s patients and paired controls and within risk groups. (Patients=red; 
Controls=yellow). 
Component 1 - (+)serum alpha-synuclein, (+)caspase-1 and (-)TLR2+ monocytes; Component 
2 - (+)serum endotoxin, (+)monocyte TREM2 and (-)serum alpha-synuclein; Component 3 -  
(+)classical monocyte percentage and (-)serum alpha-synuclein. 
 
3.5 Serum markers and clinical variables 
MDS-UPDRS motor scores correlated negatively with serum alpha-synuclein (r=-0.407; 
p=0.010) (Fig.A.8, but this did not remain significant in a multiple regression analysis with 
age, disease duration, Levodopa equivalent dose and CIRS total score as potential confounders 
(Table A.5). 
 
3.6 Principal Component Analysis (PCA) 
In order to explore relationships between key markers, a PCA was performed, using all 
participant data on all monocyte markers, and serum markers  with uncorrected significant 
results on overall PD-Control paired analysis (Appendix A).  
A three-component solution cumulatively explained 67.64% of the total variance. The principal 
component loadings of the rotated solution are shown in Table 2. Component 1 (32.48%) was 
mainly driven by (+)serum alpha-synuclein, (+)caspase-1 and (-)TLR2+ monocytes. 
Component 2 (19.48%) was mainly driven by (+)serum endotoxin, (+)monocyte TREM2 and 
less by (-)serum alpha-synuclein. Component 3 (15.67%) was mainly driven by (+)classical 




Variable Component 1 Component 2 Component 3 Communalities 
Total Monocyte TLR2+ 
percentage 
-0.880 (-0.093) (-0.042) 0.785 
Serum Caspase-1 0.801 (-0.275) (-0.093) 0.726 
Serum Endotoxin (-0.120) 0.759 (0.056) 0.594 
Total Monocyte TREM2 
MFI ratio 
(0.058) 0.673 (-0.244) 0.515 
Serum Alpha-synuclein 0.401 -0.536 -0.330 0.558 
Classical Monocyte 
percentage 
(-0.012) (-0.072)  0.936 0.881 
 
Table 2 - Principal component loadings for the rotated solution of the PCA. Coefficients 
<0.3 were suppressed and are shown in brackets. 
 
 
Paired comparisons of PCA components between PD and controls and within the risk groups 
(Fig.(4F),(G),(H)), indicated that Component 1 was significantly lower in all PD versus 
controls  (W=397, p<0.0001) and in both HR  (W=78, p=0.0256) and LR  (W=118, p=0.0001) 
groups, while Component 2 was significantly higher in all PD versus controls  (W=-299, 
p=0.0015) and within the HR group  (W=-112, p=0.0004). Component 3 was also significantly 
higher in all PD versus controls (W=-297, p=0.0016), with elevation within the LR (W=-84, 
p=0.0151) and the HR (W=-70, p=0.0479) groups. Bivariate correlation analyses did not show 




Key relationships identified through PCA were further explored, including the relationship 
between endotoxin and TREM2 (component 2) and between alpha-synuclein and caspase-1 
(component 1).  
 
3.7 Endotoxin and TREM2  
Serum endotoxin did not directly correlate with monocyte surface TREM2. However, it 
demonstrated a significant, but weak positive correlation with soluble TREM2 (r=0.1613, 
p=0.0005), which remained significant on multivariate linear regression analysis, with 
monocyte TREM2 and age as potential confounders (Fig.A.9; Table A.6). 
 
 
3.8 Alpha-synuclein and Caspase-1 
In addition to clustering within the PCA (component 1), serum alpha-synuclein and caspase-1 
were significantly positively correlated with each other (r =0.382, p=0.001)(Fig.5I). In order 
to further investigate potential mechanistic factors relating to the serum changes seen in these 
proteins (e.g. differences in cellular uptake and release), additional functional assays and 




3.8.1 Monocyte fluorescent alpha-synuclein uptake  
Monocyte uptake of fluorescent monomeric alpha-synuclein was assessed using standard 
medium, as well as an autologous serum environment (Fig.5A-D). Autologous serum was used 
to better represent the in-vivo intravascular environment (Wijeyekoon et al., 2018), while the 
standard medium was used to study the intrinsic uptake ability of the monocytes independent 
of serum factors. 
There were no significant differences in fluorescent alpha-synuclein uptake in standard 
medium between patients and controls (% positive monocytes t(35)=0.7691, 
p=0.4470)(Fig.5C,D). In autologous serum, uptake was decreased across all groups, compared 
to standard medium (t(50)=46.45, p<0.0001), but no significant case-control differences were 
seen (t(27)=1.685, p=0.1034).  
 
3.8.2 Monocyte alpha-synuclein and caspase-1 secretion 
Monocyte secretion of alpha-synuclein and caspase-1 were not significantly different between 
all PD and controls (Fig.5E-H). However alpha-synuclein secretion was decreased in HR cases 
compared to paired controls, with (t(12)=2.324, p=0.0385) and without LPS stimulation 
(t(13)=2.555, p=0.0240)(Fig.5E,G). The number of LR group pairs were insufficient for 
analysis.  
Additionally, LPS led to increased secretion of caspase-1 overall, with no relative difference 
in PD versus controls (Figure 5F,H). However, alpha-synuclein secretion did not increase with 
LPS stimulation (Figure 5E,G).  
 
3.8.3 Monocyte lysate alpha-synuclein and caspase-1 
Western blot analysis indicated the presence of higher molecular weight alpha-synuclein and 
of caspase-1 in monocyte lysates in both PD and controls (Fig.A.10A,B). Measurement of total 
alpha-synuclein and caspase-1 levels in monocyte lysates (relative to total protein) using MSD 
and ELISA assays, found no significant case-control differences (Fig.A.10C,D)). 
However, similar to the serum findings, monocyte lysate alpha-synuclein and caspase-1 were 
also positively correlated with each other (r=0.603, p=0.001)(Fig.5J).  
 
3.9 Alpha-synuclein and caspase-1 in a separate, larger incident PD cohort 
Alpha-synuclein and caspase-1 were measured in baseline plasma samples from the ICICLE-
Cambridge cohort (n=93; mean(standard deviation)-:age=66.73(6.92);disease duration 
=0.81(0.57); 60.2% male).  
The two proteins again demonstrated a significant positive correlation with each other 
(Pearson’s r=0.480, p<0.001;Fig.5K), replicating findings in the primary study cohort. There 
were no significant correlations between the baseline levels of either marker and baseline or 
longitudinal cognitive/motor measures over 36 months (data not shown). 
 
 
Figure 5 – Alpha-synuclein and Caspase-1 
(A), (B) - Fluorescence microscope images of monocytes which have taken up fluorescent 
alpha-synuclein- HiLyteTM Fluor 488 at 90minutes. Hoechst staining identifies cell nuclei. (a) 
20X; (b) 40X.  
 
(C), (D) - Monocyte fluorescent alpha-synuclein uptake in standard medium and in autologous 
serum – (C) percentage alpha-synuclein positive monocytes; (D) total monocyte MFI ratio. 
(Medium- Patients=35, Controls=35; Serum- Patients=27, Controls=28) (Patients=red; 
Controls=yellow). 
 
(E),(F),(G),(H) - Alpha-synuclein and caspase-1 in monocyte 24 hour culture supernatants 
without (E)(F) and with (G)(H) LPS, in all participants and within risk groups. (Patients = 
red, Controls= yellow).  
(All participants- Patients=18, Controls=20; Higher Risk Patients=15, Controls=16; Lower 
Risk Patients=3, Controls=4) (Patients=red; Controls=yellow). 
 
(I), (J) Graphs showing significant relationship between alpha-synuclein and caspase-1 in 
serum (I) and monocyte lysates (J).  
 
(K) ICICLE-Cambridge cohort - Relationship between alpha-synuclein and caspase-1 in 




This study evaluated key peripheral innate immune markers linked to PD, in a cohort of 
dementia risk stratified patients and carefully matched controls. The findings confirmed that 
there are significant peripheral innate immune changes in PD, with increased classical 
monocytes and TLR positive monocytes, and further demonstrated that these changes are most 
marked in those individuals at increased early dementia risk. Monocyte TREM2 expression 
was also elevated in the higher dementia risk group, while higher monocyte HLA-DR 
expression correlated  with better existing motor and cognitive performance.  
The study has also uniquely shown that innate immune changes in PD are accompanied by 
elevated serum levels of bacterial endotoxin, suggesting that this may be playing a critical role 
in driving the innate immune response and associated pathology. In addition, serum alpha-
synuclein was significantly decreased in PD, irrespective of dementia risk group and had a 
close relationship with serum caspase-1-a key component of the inflammasome pathway.  
 
PCA confirmed the clustering of markers with similar patient-control group variations. In 
particular, component 1 was mainly driven by alpha-synuclein and caspase-1 plus monocyte 
TLR2 and demonstrated significant PD-control differences overall and in both risk groups. 
Component 2 was driven by serum endotoxin, monocyte TREM2 and serum alpha-synuclein, 
with significant overall PD-control differences, predominant within the HR group. Component 
3 was driven by the classical monocyte percentage and serum alpha-synuclein, with significant 





4.1 Monocyte changes in PD  
The increase  in classical monocytes (with corresponding decrease in non-classical monocytes), 
and monocyte TLR2+ and TLR4+ monocytes observed in this PD cohort confirms previous 
findings (Grozdanov et al., 2014)(Drouin-Ouellet et al., 2015). However, this study further 
demonstrates that these changes are mainly driven by those at increased risk of dementia.  
 
Classical monocytes (up to 85% of total monocytes)  are mainly involved in phagocytosis, 
antigen presentation to adaptive immune cells and cytokine secretion in response to TLR 
stimulation (Wong et al., 2012)(Mukherjee et al., 2015), although exact subtype functions may 
vary under different clinical conditions  (J. Lee et al., 2017)(Boyette et al., 2017). Intermediate 
and non-classical monocytes may also be more senescent cells, that increase with age (Ziegler-
Heitbrock and Hofer, 2013) and derive from further differentiation of classical monocytes in 
the bone marrow (Ong et al., 2018)(Patel et al., 2017). At a systemic level, LPS stimulation 
leads to depletion of  monocyte numbers and on recovery, classical monocytes appear to rise 
first (Tak et al., 2017). Thus, the increased classical monocytes seen in PD compared to 
controls, most prominent in the HR group, may reflect chronic exposure to the increased 
endotoxin, in these patients. The data is also consistent with our previous finding of reduced 
senescence markers in T lymphocytes in PD cases in this cohort (Williams-Gray et al., 2018).  
 
 
The TLR2+ monocyte percentage varied inversely to alpha-synuclein and caspase-1 in PCA 
component 1. TLR2 is an innate immune receptor to DAMPs/PAMPs(e.g. bacterial-derived 
lipids, amyloids) and endogenous ligands including forms of alpha-synuclein (Bryant et al., 
2015) (Kim et al., 2013)(Kim et al., 2016a)(Codolo et al., 2013), and can also facilitate 
activation of the inflammasome pathway (Rapsinski et al., 2015) and caspase-1.  
TLR4 has a major role in the transduction of the cellular response to bacterial endotoxin and 
its stimulation leads to activation of Nuclear factor-kappa B (NF-κB) and transcription of 
cytokine  precursors (e.g.IL-6, IL-1β) and inflammasome components (Lu et al., 2008), 
potentially leading to a relative ‘priming’ effect on inflammasome activation in patients.  
Thus, the TLR2 and TLR4 monocyte changes seen may reflect increased potential to respond 
to DAMPS/PAMPS including alpha-synuclein, with subsequent promotion of caspase-1 
activation, intracellular accumulation/aggregation and inflammation, mainly in the HR 
patients.  
 
Significant elevation of monocyte TREM2 was also observed in the HR patient group. TREM2 
is involved in bacterial clearance during sepsis (Chen et al., 2013) and may have a role in 
regulating TLR pathway signalling (Hamerman et al., 2006)(Kober and Brett, 2017). Increased 
monocyte TREM2 expression is seen in Alzheimer’s disease (Hu et al., 2014) and TREM2 can 
act as a microglial receptor for amyloid-beta, with involvement in phagocytosis and clearance 
of Alzheimer’s pathology (Zhao et al., 2018)(Lee et al., 2018). Interestingly, this may suggest 
that TREM2 may be raised in response to chronic TLR stimulation and indicates possible 
immunological similarities between high dementia risk PD and Alzheimer’s disease.  
 
Monocyte HLA-DR expression did not differ between PD cases and controls, but did 
significantly correlate with clinical variables in disease (lower levels associated with worse 
cognitive/motor function). Low monocyte HLA-DR is a key feature of monocyte tolerance, 
typically known to occur subsequent to stimuli such as LPS/endotoxin or sepsis,  and is 
associated with decreased antigen presentation, cytokine production and changes in 
phagocytosis, and mediated by epigenetic and metabolic factors (Pfortmueller et al., 
2017)(Saeed et al., 2014)(Cheng et al., 2014). These immune disruptions associated with low 
HLA-DR may contribute to impaired clearance of pathological proteins, neuronal dysfunction 
and subsequent cognitive and motor impairment. In contrast, PD animal models involving 
acute toxin/protein injections/pathology suggest deleterious effects of increased HLA-DR 
(Williams et al., 2018)(Harms et al., 2013). This may indicate that in the acute situation seen 
in animal models, the detrimental effects of HLADR (e.g.pro-inflammatory cytokine release) 
outweigh the beneficial effects of increased antigen presentation/clearance, whereas in the 
chronic clinical situation, the beneficial effects of increased HLA-DR mediated pathology 
clearance outweigh the detrimental effects. However, more detailed prospective studies will be 
required to further investigate these effects and hypotheses. 
 
The PD-control marker changes seen in total monocytes may mainly reflect changes seen in 
the pre-dominant classical monocyte subtype. However, analysis of the more limited data from 
Intermediate and Non-Classical monocytes also indicated broadly similar trends in these 
subtypes overall (Appendix A). Further detailed studies specifically investigating monocyte 
subtype and related innate immune cell (e.g. dendritic cell) changes in PD will be important in 
future work.  
 
 
4.2 Serum Endotoxin 
To our knowledge, this is the first study to directly demonstrate elevated serum endotoxin in 
PD, particularly in patients with increased risk for early dementia. Endotoxin is a principal 
component of the outer membrane of gram-negative bacteria and its major source in serum is 
translocation of gram-negative bacterial components across gastrointestinal/other mucosal 
membranes (Bischoff et al., 2014) (Kelesidis et al., 2012)(Alexopoulou et al., 2017) and thus 
the findings indicate greater bacterial translocation in PD, particularly in the HR group.  
 
Accordingly, previous studies have demonstrated greater gastrointestinal permeability in PD 
patients, with lower levels of LPS binding protein (LBP) (indicating less LPS neutralisation) 
and increased gut staining for Escherichia Coli bacteria (Forsyth et al., 2011)(Perez-Pardo et 
al., 2019). One smaller study (Hasegawa et al., 2015) found no difference in serum endotoxin, 
but lower LBP (Pal et al., 2015)(Vreugdenhil et al., 2003) in PD patients, suggesting an LPS-
LBP imbalance with increased LPS activity. Intestinal microbiome differences are also seen in 
PD (Scheperjans et al., 2015) and may modulate disease pathology and manifestation 
(Sampson et al., 2016)(Dodiya et al., 2018).  
 
Low level chronic elevation of serum endotoxin in PD may be an important mediator of innate 
immune changes. At a cellular level, endotoxin/LPS acts via TLR4, activating NF-κB and 
transcription of pro-inflammatory cytokines and proteins including pro-IL-1β and NLRP3 (Lu 
et al., 2008). Intracellular LPS can also activate the non-canonical NLRP3 inflammasome 
pathway via  caspase-11 (caspase-4 or -5 in humans), leading to caspase-1 activation (Man and 
Kanneganti, 2015)(Stowe et al., 2015). Thus, endotoxin would stimulate both TLR and 
inflammasome pathways, potentially resulting in cumulative pathogenic effects.  
Endotoxin also has direct effects on alpha-synuclein, stimulating increased production in 
macrophages (Tanji et al., 2002) and specific fibril formation (Kim et al., 
2016b)(Bhattacharyya et al., 2019). Furthermore, in-vivo studies have demonstrated 
synergistic deleterious effects of LPS and alpha-synuclein on PD related pathology and 
neuronal survival (H.-M. Gao et al., 2011)(Zhang et al., 2018). Amyloid beta and tau 
pathology, which are additionally related to cognitive impairment, have also been linked to 
endotoxin-associated inflammation (Asti and Gioglio, 2014)(Kitazawa et al., 2005), with LPS 
stimulation leading to increased tau production (Bhaskar et al., 2010)(Gardner et al., 2016).  
 
Peripheral endotoxin may also lead to neuroinflammation in the brain, as measured using PET 
imaging of microglial activation in human subjects following peripheral intravenous injection 
of low dose LPS (Sandiego et al., 2015). It is unclear whether the microglial activation is a 
direct consequence of endotoxin in CNS tissues, or of secondary immune cell/protein CNS 
entry. However, post-mortem studies have found LPS/microbial proteins in relation to 
amyloid-beta plaques in Alzheimer’s disease brains, indicating the presence of endotoxin itself 
within the brain (Zhan et al., 2016).  
As discussed above, variable extent and duration of serum endotoxin exposure (Morris et al., 
2015) may also subsequently influence disease pathology through monocyte tolerance and 
effects on HLA-DR/protein clearance functions (Mukherjee et al., 2015)(Kobayashi et al., 
2016)(de Lima et al., 2014), in addition to driving an innate immune response and promoting 
aggregation, particularly in the HR group.  
 
PCA Component 2 indicated a possible relationship between endotoxin and monocyte TREM2. 
As discussed above, TREM2 is involved in bacterial clearance (Chen et al., 2013) and may be 
raised in response to elevated endotoxin and TLR signalling in PD (Hamerman et al., 
2006)(Kober and Brett, 2017). Opposite to this elevation seen in HR PD, monocyte TREM2 is 
decreased in LR PD relative to controls, consistent with the lack of rise in endotoxin/TLR in 
LR PD. Furthermore, serum endotoxin was positively correlated with sTREM2, which would 
be consistent with the sTREM2 rise seen with infection related immune activation (Gisslén et 




4.3 Alpha-synuclein and Caspase-1 
Serum alpha-synuclein and caspase-1 (major factors in PCA component 1), were significantly 
lower in PD compared to controls regardless of risk group. The study has also discovered a 
positive relationship between these proteins in serum, plasma and monocyte lysates. This 
would be consistent with co-accumulation/aggregation and/or parallel changes in production 
and breakdown.  
Alpha-synuclein is physiologically produced, released and taken up by many cells, including 
peripheral blood cells (Shin et al., 2000)(Barbour et al., 2008)(Tyson et al., 2016) and 
decreased levels are seen in PD blood (Gupta et al., 2015)(Li et al., 2007)(Ishii et al., 2015) 
and cerebrospinal fluid (CSF) (Eusebi et al., 2017).  This may suggest alpha-synuclein is being 
sequestered out of bio-fluids by aggregation and/or intracellular accumulation. Higher patient 
plasma alpha-synuclein found in some studies (Lin et al., 2017)(Duran et al., 2010), may relate 
to red cell/platelet leakage during centrifugation (Shi et al., 2010).  
The decreased monocyte alpha-synuclein release seen in the HR patient group may be an 
additional contributor to lower serum alpha-synuclein in this group and could relate to 
exocytosis dysfunction in PD (Lautenschläger et al., 2017)(Logan et al., 2017).  Further, 
increased aggregated  alpha-synuclein species found in PD  (Parnetti et al., 2019) may also 
cause confounding issues with detection by the immunoassays used.   
 
Caspase-1, a key component of the inflammasome pathway (Strowig et al., 2012), is produced 
by many cell types, including monocytes (Shamaa et al., 2015). Activation of inflammasome 
complexes (e.g. Nucleotide-binding domain, leucine rich repeat containing receptor family 
pyrin domain containing-3(NLRP3)) (Strowig et al., 2012)(Man and Kanneganti, 2015), 
triggered by a variety of stimuli related to homeostatic disruption  (e.g. microbial/viral 
RNA/DNA components, ATP, uric acid) (Man and Kanneganti, 2015), leads to  activation of 
caspase-1, which subsequently cleaves other proteins (e.g. pro-IL-1β, pro-IL-18), leading to 
inflammation.  
Activated caspase-1 can also cleave alpha-synuclein, making it more aggregable  (Wang et al., 
2016) and our observation of decreased serum caspase-1 and its correlation with alpha-
synuclein may suggest they are both being sequestered out of serum, possibly into cells or 
aggregates, as a common process in PD. Studies, including our own work (White et al., 2018), 
have also shown that alpha-synuclein can activate inflammasome pathways causing 
inflammatory cytokine production (Codolo et al., 2013)(Zhou et al., 2016). Hence both alpha-
synuclein and caspase-1 may interact in a bidirectional loop, which contributes to both 
increased inflammation and intracellular alpha-synuclein aggregation in PD.  
In contrast to the current study, Zhou et al. found increased caspase-1 in a smaller cohort of 
twelve patients compared to controls (Zhou et al., 2016). However, differences in 
patient/control demographics and longer delays prior to higher speed centrifugation (increasing 
leakage risk of intracellular caspase-1) in that study, may have contributed to the differences. 
The alpha-synuclein and caspase-1 related monocyte assays may additionally suggest 
functional impairment of monocytes in PD. Previous studies have found TLR4-mediated 
stimulation of microglial phagocytosis and alpha-synuclein uptake (Fellner et al., 
2013)(Venezia et al., 2017) and increased caspase-1 release on endotoxin stimulation of 
PBMCs (White et al., 2018). However, PD monocytes in this study demonstrated no increased 
alpha-synuclein uptake or LPS-induced caspase-1 secretion, contrary to what might be 





4.4 Relevance of peripheral immune changes to PD pathology 
Peripheral changes in alpha-synuclein and innate immune and microbial related molecules may 
provide relevant insights into PD pathogenesis and heterogeneity. In particular, multiple routes 
of communication between the CNS and periphery, (including lymphatic routes (Louveau et 
al., 2015), blood/brain barrier, choroid plexus, CSF, meninges and the peripheral/autonomic 
nervous system (Su and Federoff, 2014)), indicate that peripheral changes could be influenced 
by and/or influence CNS pathology. Importantly, peripheral LPS injection in humans leads to 
rapid central microglial activation on PET imaging and highlights the strength of influence of 
peripheral immune factors on the CNS (Sandiego et al., 2015).  
 
Alpha-synuclein pathology is present in the gut and periphery as well as the brain in PD 
(Forsyth et al., 2011) and some of the peripheral immune changes observed may be directly 
reflective of such pathology. Also, peripheral factors such as the microbiome (e.g. gut) may 
have parallel peripheral immune and CNS effects (Marizzoni et al., 2017), including in PD 
(Scheperjans et al., 2015)(Unger et al., 2016). 
 
In addition to potential direct contributions towards the pathology, peripheral monocytes 
constitute an easily repeatedly accessible source of cells from a living patient and may provide 
insights into generic cellular processes disrupted in PD. While monocytes are considered to 
contribute towards choroid plexus macrophages (Kierdorf et al., 2019), genetic variations in 
central microglia function have been paralleled in related peripheral monocytes (Bradshaw et 
al., 2013), indicating that monocytes could act as peripheral proxies or models for particular 
aspects of study of microglia and CNS innate immune cells in PD. 
 
 
4.5 Limitations  
Our sample size was limited by the feasibility of collecting patient-control samples paired by 
age, gender and MAPT haplotype for parallel processing of samples. Although this was 
advantageous in terms of ensuring that each patient-control pair experienced minimal 
variations due to methodological issues, it limited power which may explain our inability to 
detect previously observed differences in inflammatory cytokines(Williams-Gray et al., 
2016)(Qin et al., 2016). In addition, despite practical corrections for multiple comparison 
testing, we cannot exclude the possibility of Type I errors. 
 
Dopamine may influence immune cell properties (Papa et al., 2017) and 
Levodopa/dopaminergic medications could therefore cause potential confounding effects. 




The observed changes in monocyte and serum markers indicate significant innate immune 
involvement in early-moderate PD, with differential and more marked effects in those with 
greater clinical impairment and at increased risk for early cognitive decline, suggesting that 
certain immune changes may be relevant to faster disease progression. Relevant mechanistic 
pathways and hypothesized interactions are summarised in Fig.6.  
 
 
Figure 6 – Summary 
Schematic diagram of key innate immune related markers, pathological pathways and 
hypothesised interactions relevant to clinical progression in Parkinson’s disease, based on 
insights from this study and previous literature. The cellular section represents any cell in 
which the relevant markers/processes are present. The outcomes of these processes, together 
with decreased clearance and circulatory spread, could ultimately contribute towards 
increased neuronal/synaptic dysfunction, cortical pathology, and consequent cognitive/clinical 
progression.  
LPS – Lipopolysaccharide (Endotoxin); DAMPs/PAMPs – Damage/Pathogen Associated 
Molecular Patterns; NF-κB – Nuclear Factor Kappa B; TREM2- Triggering Receptor 
Expressed on Myeloid cells-2; HLA-DR- Human Leukocyte Antigen-DR subtype; TLR- Toll-
Like Receptor; IL- Interleukin; TNF – Tumour Necrosis Factor.  
 
 
Higher endotoxin in those patients with higher dementia risk suggests that greater microbial 
translocation may be an important factor in driving pathology, whilst the association between 
low monocyte HLA-DR and poor clinical status suggests that impaired antigen presentation 
may also contribute to increased pathology and neurodegeneration.  
Alpha-synuclein and caspase-1 appear to be closely associated and may have reciprocal effects 
which contribute to inflammasome activation and intracellular alpha-synuclein aggregation in 
all PD.  
 
The findings need to be replicated and the extent to which the clinical differences are simply 
correlated with, or are a consequence of, immune changes will require further prospective 
longitudinal studies. Measurement of serum LBP and other microbial translocation markers 
(e.g. bactericidal-permeability increasing protein (BPI) (Alexopoulou et al., 2017)), epigenetic 
markers associated with monocyte endotoxin tolerance and other inflammasome pathway 
components (e.g. NLRP3 and Apoptosis-associated Speck-like protein containing a C-terminal 
caspase-recruitment domain (ASC) specks (Gordon et al., 2018)(Franklin et al., 2018)) would 
provide further insights into involvement of these pathways in PD.  
 
 
A clearer mechanistic understanding of how innate immune pathways contribute to disease 
progression and dementia may open up new therapeutic avenues and enable targeted trials of 
specific immune/microbial related therapies (e.g. caspase-1 /inflammasome inhibitors (Bassil 
et al., 2016)(Flores et al., 2018)(Coll et al., 2015), TLR antagonists (Lucas and Maes, 
2013)(Peri and Piazza, 2012)(Kouli et al., 2019), and gut bacterial translocation reduction 
therapies (Fukui, 2017)(Gangarapu et al., 2015)) in particular subgroups. Improving 
constipation/gastrointestinal health, and prevention/early treatment of infections may also be 
of relevance, while specific markers may have additional value as biomarkers to monitor target 
engagement of immune-directed therapies. Further detailed investigation of the components 
and relationships highlighted in this study will be essential for progression towards such 
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9. Figure Legends 
Figure 1 – Monocyte subtypes  
(A) - Flow cytometry gating strategy for monocytes and monocyte subtypes Singlets are 
identified by plotting Forward Scatter-Area (FSC-A) versus Forward Scatter-Width (FSC-W) 
and excluding cells with multiples of a single width size. Monocyte, lymphocytes and 
granulocytes are distinguished using FSC-A (size) and Side Scatter-Area (SSC-A) 
(granularity/internal complexity). Monocyte subtypes are distinguished based on CD14 and 
CD16 expression –Classical (CD14 high, CD16 negative); Intermediate (CD14 high, CD16 
positive); Non-Classical (CD14 low, CD16 high).  
(B) - Total monocytes (as a percentage of PBMCs) in all patients and controls; overall and 
within dementia risk groups (Parkinson’s disease=red; Controls=yellow).  
(C),(D),(E)-Monocyte Subtypes. (C) Classical, (D) Intermediate and (E) Non-Classical 
monocytes (as percentage of total monocytes) in Parkinson’s disease patients and controls; 
overall and within dementia risk groups (Parkinson’s disease=red; Controls=yellow). 
**significance withstood Bonferroni correction for multiple testing within the relevant 
category. 
 
Figure 2 – Monocyte surface markers 
Total monocyte marker expression in Parkinson’s disease cases versus paired controls; overall 
and within risk groups.  Graphs showing total monocyte MFI (Median Fluorescence Intensity) 
ratios (Test/Isotype) ((A), (C), (E), (G)) and percentage monocytes positive ((B), (D), (F), (H)). 
(Parkinson’s disease=red; Controls=yellow). **significance withstood Bonferroni correction 
for multiple testing within the relevant category. 
 
Figure 3 – Monocyte HLA-DR expression and clinical data 
Relationships between Total Monocyte HLA-DR expression (Test/Isotype MFI Ratio) and 
clinical data - (A) Semantic Fluency. (B) MDS-UPDRS III motor score. (C) ACE-R score. (D) 
Absence of correlation with Levodopa equivalent dose.  
 
Figure 4 – Serum markers and Principal Components Analysis  
(A)-(E) - Concentrations of serum (A) alpha-synuclein, (B) caspase-1, (C) endotoxin, (D) 
soluble CD14 and (E) soluble TREM2 in Parkinson’s disease patients and controls and within 
Parkinson’s dementia risk groups. (Patients=red; Controls=yellow). **significance withstood 
Bonferroni correction for multiple testing within the relevant category. 
(F)-(H) - Summary of Principal Components Analysis (PCA) component score comparisons 
between all Parkinson’s patients and paired controls and within risk groups. (Patients=red; 
Controls=yellow). 
Component 1 - (+)serum alpha-synuclein, (+)caspase-1 and (-)TLR2+ monocytes; Component 
2 - (+)serum endotoxin, (+)monocyte TREM2 and (-)serum alpha-synuclein; Component 3 -  






Figure 5 – Alpha-synuclein and Caspase-1 
(A), (B) - Fluorescence microscope images of monocytes which have taken up fluorescent 
alpha-synuclein- HiLyteTM Fluor 488 at 90minutes. Hoechst staining identifies cell nuclei. (a) 
20X; (b) 40X.  
 
(C), (D) - Monocyte fluorescent alpha-synuclein uptake in standard medium and in autologous 
serum – (C) percentage alpha-synuclein positive monocytes; (D) total monocyte MFI ratio. 
(Medium- Patients=35, Controls=35; Serum- Patients=27, Controls=28) (Patients=red; 
Controls=yellow). 
 
(E),(F),(G),(H) - Alpha-synuclein and caspase-1 in monocyte 24 hour culture supernatants 
without (E)(F) and with (G)(H) LPS, in all participants and within risk groups. (Patients = red, 
Controls= yellow).  
(All participants- Patients=18, Controls=20; Higher Risk Patients=15, Controls=16; Lower 
Risk Patients=3, Controls=4) (Patients=red; Controls=yellow). 
 
(I), (J) Graphs showing significant relationship between alpha-synuclein and caspase-1 in 
serum (I) and monocyte lysates (J).  
 
(K) ICICLE-Cambridge cohort - Relationship between alpha-synuclein and caspase-1 in 
plasma samples collected at study baseline.  
 
Figure 6 – Summary 
Schematic diagram of key innate immune related markers, pathological pathways and 
hypothesised interactions relevant to clinical progression in Parkinson’s disease, based on 
insights from this study and previous literature. The cellular section represents any cell in which 
the relevant markers/processes are present. The outcomes of these processes, together with 
decreased clearance and circulatory spread, could ultimately contribute towards increased 
neuronal/synaptic dysfunction, cortical pathology, and consequent cognitive/clinical 
progression.  
LPS – Lipopolysaccharide (Endotoxin); DAMPs/PAMPs – Damage/Pathogen Associated 
Molecular Patterns; NF-κB – Nuclear Factor Kappa B; TREM2- Triggering Receptor 
Expressed on Myeloid cells-2; HLA-DR- Human Leukocyte Antigen-DR subtype; TLR- Toll-















1.1 PBMC isolation, Immunocytochemistry and Flow Cytometry 
PBMCs were extracted using the standard Ficoll gradient centrifugation method (Ficoll R 
Paque Plus, GE Healthcare). Cell suspensions obtained following Ficoll gradient separation 
were centrifuged, and cell pellets were blocked with fluorescence activated cell sorting (FACS) 
buffer with 2% mouse serum (Sigma) per 0.5–1 × 106 cells. Following blocking for 30min, the 
PBMCs were stained with a panel of conjugated antibodies detailed in Table A.1 and incubated 
at 4°C for 30min. Following incubation, the PBMCs were washed, fixed with 2% 
paraformaldehyde (PFA) and then re-suspended in FACS buffer for flow cytometry. Flow 
cytometry was performed using the BD LSR Fortessa machine with BD FACS Diva software.  
Monocytes were gated as described in the literature (Ziegler-Heitbrock and Hofer, 2013) 
(Givan A.L., Flow cytometry: first principles, 2001) and a minimum number of 10,000 
monocyte events were collected per sample. PBMCs from healthy controls, labeled with single 
conjugated antibodies, were used to determine the appropriate compensation for spectral 
overlap of fluorophores. Flow cytometry data was analyzed using Flow Jo software, version 
10. The percentage of marker positive cells and marker expression levels were determined with 
reference to isotype control samples (Median Fluorescence Intensity (MFI) Test/Isotype ratio). 
 
 
The PBMC extractions and staining were performed throughout at 4°C, limiting cell death. 
During preparatory work for this study, a Live-Dead differentiation stain (LIVE/DEAD™ 
Fixable Violet Dead Cell Stain, ThermoFisher) was used to assess the percentage of dead cells 
(Figure A.1). The majority of monocytes (~99.8%) were negative for the Live-Dead stain and 
positive numbers were not considered to significantly influence the final analysis. Therefore, 
the Live-Dead stain was not used routinely in this study. 
 
Figure A.1- Live-Dead stain – Flow cytometry plots demonstrating the use of the Live-Dead 
stain ex-vivo for estimation of the percentage of dead cells.  
 
Flow cytometry analysis was performed on total monocytes using a standard method based on 
a tight gate using the FSC-SSC plot (Figure 1A) (Givan AL. Flow cytometry : first principles. 
Wiley-Liss 2001)(Tadema et al., 2011), due to the availability of more complete data (problems 
with the CD14-CD16 staining in a few samples). While this gate may also include a small 
proportion of related innate immune cells such as dendritic cells, available data indicated that 
>91% of the FSC-SSC gated monocytes were also monocytes based on CD14-CD16 plot 
gating.  
 
Additional analysis was performed on Classical (CD14high/CD16negative), Intermediate 
(CD14high/CD16positive) and Non-Classical (CD14low/CD16high) monocytes. However, 
the numbers of captured Intermediate and Non-Classical monocytes per sample were 
considered too low for sufficiently robust analysis and conclusions in this study.  
 
Antibody (anti-Human) Isotype Control Volume used (µl) 
CD14 – APC-H7 (MφP9, mouse 
mAb, BD Biosciences) 
Mouse IgG2b κ (27-35, mouse 
mAb, BD Biosciences) 
2 
CD16 – PerCP-Cy5.5 (3G8, 
mouse mAb, BioLegend) 
Mouse IgG 1 κ (MOPC-21, 
mouse mAb, BioLegend) 
1 
HLA-DR – BV605 (L243, mouse 
mAb, BioLegend) 
Mouse IgG 2a κ (MOPC-173, 
mouse mAb, BioLegend) 
5 
TREM2 –APC (#237920, rat 
mAb, R and D Systems) 
Rat IgG 2B (#141945, rat mAb, 
R and D Systems) 
10 
TLR2 – PE (TL2.1, mouse mAb, 
Biolegend) 
Mouse IgG 2a κ (MOPC-173, 
mouse mAb, BioLegend) 
5 
TLR4 – BV421 (X40, mouse 
mAb, Biolegend)  




Table A.1- Antibodies used for immunocytochemistry and flow cytometry.  
CD – Cluster of Differentiation; HLA-DR (Human Leukocyte Antigen-DR), TREM2 
(Triggering Receptor Expressed on Myeloid cells 2); TLR (Toll like Receptor).  
 
 
1.2 Serum sample processing and assays 
Blood samples taken for serum collection were left to clot for 15 minutes. Samples were 
centrifuged at 2000rpm for 15 minutes at room temperature. The separated serum was stored 
in 200-400 µl aliquots and frozen at -80°C.   
 
Mesoscale Discovery (MSD) platform electrochemiluminescence assays 
(https://www.mesoscale.com). 
MSD assay general protocol 
Samples were analysed according to the manufacturer’s instructions. Briefly, serum samples, 
stored at -80ºC, were thawed to room temperature. The samples were diluted as specified in 
the appropriate buffer and loaded in duplicate onto the MSD plates at the specified volume per 
well. A serial dilution series of manufacturer provided standard samples were also loaded in 
duplicate. The plate was incubated at room temperature on a shaker for the appropriate time 
period and washed three times using Phosphate Buffered Saline (PBS) with 0.05% Tween 
(wash buffer). The specified volume of detection antibody was added at the appropriate 
concentration and the plate was incubated on the shaker for a further time period. Following 
removal of the detection antibody, the plate was washed three times and 150µl of 1X or 2X 
Read buffer was added to each well. Readings were obtained using the MSD SECTOR Imager. 
Data was exported and analysed using the MSD Discovery Workbench software.  
 
MSD V-Plex Pro-inflammatory panel 1 assay 
Samples were analysed for Interferon (IFN)-γ, Interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-
10, IL-12p70, IL-13 and Tumour Necrosis Factor (TNF)-α in a multiplexed 10-spot 96 well 
plate. Samples were diluted 1:2 and used at 50ul per well. 25µl of the detection antibody and 
2X Read buffer were used. Both the initial and second incubation times were 2 hours.  
 
MSD V-Plex Human CRP assay 
Samples were analysed for C-Reactive protein (CRP) in a single spot 96 well plate. Samples 
were diluted 1:1000 and used at 25ul per well. 25µl of the detection antibody and 1X Read 
buffer were used. The initial incubation period was 2 hours, while the second incubation period 
was 1 hour.  
 
MSD Human Alpha-Synuclein Assay 
Samples were analysed for alpha-synuclein in a single spot 96 well plate. Samples were diluted 
1:10 and used at 25ul per well. 25µl of the detection antibody was added together with the 
samples and the plate was incubated only once for 2 hours prior to washing. 2X Read buffer 
were used.  
 
Serum Endotoxin – Limulus Amoebocyte Lysate (LAL) Assay 
The assay was carried out using the Pierce LAL Chromogenic Endotoxin Quantitation Kit 
(Thermo Scientific) (40 samples) and the LAL Chromogenic Endpoint Assay (Hycult Biotech) 
(36 samples), due to supplier shortages during the time of performing the assays. Samples from 
patient and control pairs were analysed in the same plate using the same kit. The results of 
samples from both batches covered similar ranges (Thermo Scientific kit – 0.46 – 6.32 EU/ml; 




Pierce LAL Chromogenic Endotoxin Quantitation Kit (Thermo Scientific) 
The assay was performed in duplicate according to the manufacturer’s instructions. Briefly, 
following pre-incubation of the microplate at 37ºC, 50µL of each standard or sample (diluted 
1:50) was inserted into the appropriate microplate well.  The plate was covered and incubated 
for 5 minutes at 37ºC. 50µL of LAL was added to each well following which the plate was 
incubated at 37ºC for 10 minutes. 100µL of substrate solution was added to each well, followed 
by incubation at 37ºC for 6 minutes. 50µL of Stop Reagent (25% acetic acid was added and 
the absorbance at 405-410nm was measured using the FLUOstar Omega microplate reader 
(BMG LABTECH). The average absorbance of the blank replicates was subtracted from the 
average absorbance of all individual standard and unknown sample replicates. A standard curve 
was prepared by plotting the average blank-corrected absorbance for each standard versus its 
concentration in EU/mL and this was used to determine the endotoxin concentration of each 
unknown sample. 
LAL Chromogenic Endpoint Assay (Hycult Biotech) 
The assay was performed in duplicate according to the manufacturer’s instructions. Briefly, 
50µl of sample (diluted 1:50) or standard was added to the assigned wells. 50µl/well of 
reconstituted LAL reagent was added and the plate was covered and incubated for 30 minutes 
at room temperature. The reaction was stopped by adding 50µl 1x stop solution and the 
absorbance at 405 nm was measured using the FLUOstar Omega microplate reader (BMG 
LABTECH). A standard curve was prepared by plotting the average blank-corrected 
absorbance for each standard versus its concentration in EU/mL and this was used to determine 




Serum Caspase 1 ELISA 
Samples were analysed using the Human Caspase 1 Quantikine ELISA kit (R and D Systems). 
The assay was carried out using the manufacturer’s instructions and samples were analysed in 
duplicate. Samples from patient and control pairs were analysed on the same plate. Briefly, 
50μL of Assay Diluent was added to each well, followed by 100μL of Standard or sample 
applied in duplicate. The plate was incubated for 1.5 hours at room temperature on a shaker, 
followed by aspiration and three washes with ~400µl of wash buffer per well. 100μL of 
Caspase-1 Antiserum was added to each well and incubated for 30 minutes at room 
temperature. The aspiration/wash process was repeated and 100μL of Human Caspase-1 
Conjugate was added to each well, followed by a further incubation of 30 minutes. The 
aspiration/wash process was repeated and 200μL of Substrate Solution was added to each well, 
followed by 20 minutes incubation protected from light. 50μL of Stop Solution was then added 
and the optical density of each well was determined within 30 minutes, using the FLUOstar 
Omega microplate reader (BMG LABTECH) set to 450 nm. Readings at 540 nm or 570 nm 
were subtracted from the readings at 450 nm to correct for optical imperfections in the plate. 
In calculating the results, the average zero standard optical density was subtracted from all 
readings. A standard curve was plotted and used to calculate the caspase-1 concentrations for 
the samples.  
 
Serum soluble TREM2 ELISA 
Samples were analysed using the Cloud-Clone Corp. ELISA kit for TREM2. The assay was 
carried out using the manufacturer’s instructions and samples were analysed in duplicate. 
Samples from patient and control pairs were analysed on the same plate. Samples were diluted 
1:2 with PBS based on the manufacturer’s guidance and sample trials.  
100µL of standard or sample was added to each well, followed by incubation for 1 hour at 
37°C. This was aspirated, followed by the addition of 100µL of Detection Reagent A and 
further incubation for 1 hour at 37°C. The wells were aspirated and washed three times, 
followed by the addition of 100µL of Detection Reagent B and a further incubation for 30 
minutes at 37°C. The wells were then aspirated and washed five times, followed by the addition 
of 90µL of Substrate Solution and incubation for 10-20 minutes at 37°C protected from light. 
50µL of Stop Solution was then added and the absorbance was read immediately using the 
FLUOstar Omega microplate reader (BMG LABTECH) at 450nm. 
In calculating the results, the average zero standard optical density was subtracted from all 
readings. A standard curve was plotted and used to calculate the soluble TREM2 concentration 
in the samples.  
 
Serum soluble CD14 ELISA 
Samples were analysed using the Human soluble CD14 Quantikine ELISA kit (R and D 
systems). The assay was carried out using the manufacturer’s instructions and samples were 
analysed in duplicate. Samples from patient and control pairs were analysed on the same plate. 
Samples were diluted 1:800 based on the manufacturer’s guidance and sample trials. Briefly, 
100μL of Assay Diluent was added to each well, followed by 100μL of standard or sample per 
well in duplicate. The plate was sealed and incubated for 3 hours at room temperature. 
Following this all wells were aspirated and washed 4 times using ~400µl of Wash Buffer per 
well. 200μL of Human CD14 Conjugate was added to each well, followed by a further 
incubation for 1 hour at room temperature. The plate was then washed 4 times as above and 
200μL of Substrate Solution was added to each well, followed by incubation for 30 minutes at 
room temperature, protected from light. 50μL of Stop Solution was added to each well and the 
optical density of each well was determined within 30 minutes, using the FLUOstar Omega 
microplate reader (BMG LABTECH) set to 450 nm.  
Readings at 540 nm or 570 nm were subtracted from the readings at 450 nm to correct for 
optical imperfections in the plate. In calculating the results, the average zero standard optical 
density was subtracted from all readings. A standard curve was plotted and used to calculate 
the soluble CD14 concentration in the samples.  
 
1.3 Monocyte separation 
CD14+ cells were separated from PBMCs using MACS® magnetic CD14+ beads (Miltenyi 
Biotec) and “LS” columns, according to the manufacturer’s instructions. Both manual and 
automatic methods of MACS® magnetic bead cell separation (Miltenyi Biotec) were used due 
to limited availability of equipment. Both methods produced similar results in terms of cell 
purity and yield. The majority of the samples were separated manually, and all patient and 
control pairs were separated using the same method.  
 
Manual separation 
PBMCs were re-suspended in cooled ‘MACS’ buffer (1XPBS, 5mg/ml BSA, 2mM EDTA) at 
a concentration of 80µl/107cells. The CD14 magnetic bead suspension (Miltenyi Biotec) was 
added to the cells at a concentration of 20µl per 107 cells and incubated at 4ºC for 30 minutes. 
The cells were washed and re-suspended in ~1ml of MACS buffer. This was added to a pre-
rinsed ‘LS’ separation column which was placed within the MidiMACSTM magnet separator 
(Miltenyi Biotec). Once the solution had run through, the column was washed three times with 
3ml cool MACS buffer. Finally, the column was removed from the magnet, allowing the 
magnetic bead labelled cells (CD14+) in the column to be eluted with 5ml of MACS buffer 
into a 15ml Falcon tube.  
 
Separation using the autoMACS® Pro Separator machine 
The autoMACS machine (Miltenyi Biotec) was programmed for CD14 positive selection and 
the CD14+ beads and the sample and collection tubes were placed appropriately for automatic 
labelling and separation. The programme was run, and the negative and positive fractions of 
cells were collected in 15ml Falcon tubes.  
 
1.4 Monocyte uptake assays  
Fluorescent alpha-synuclein endocytosis assays 
Titration and time course experiments were performed prior to the start of the study to optimise 
the concentrations and end time points for the assays. 
 
Uptake assay protocol 
CD14+ cells were centrifuged at 350g for 5 minutes and re-suspended in clear RPMI (Roswell 
Park Memorial Institute culture medium) (Life Technologies) + 10% FCS (Foetal Calf Serum) 
(Sigma) (200µl per 0.5 x 106 monocytes). The cells were placed in 96 well plates at a 
concentration of 0.5 x 106 monocytes in 200ul per well and equilibrated in the incubator (37ºC, 
5% CO2) (Test plates) or the fridge (4ºC plates) for 45minutes.  
 
Following this, recombinant human alpha-synuclein (1-140) HiLyteTM Fluor 488 (Anaspec) 
(2µl of 1µg/µl solution to give a concentration of 10 ng/µl or 10,000ng/ml) was added and 
mixed into the appropriate wells. The Test plates were placed in the incubator (37ºC, 5% CO2) 
to simulate in vivo conditions, while the 4ºC plates were placed in the fridge, as monocyte 
phagocytosis and endocytosis should be inhibited at 4ºC and were used as a reference to 
account for any non-specific adherence of the proteins to the cells.  
The concentration of alpha-synuclein was based on titration experiments, which used 
concentrations of 100, 1000 and 10,000 ng/ml. Minimising the time period of uptake, while 
enabling adequate quantification using flow cytometry, required the use of a high concentration 
of 10,000ng/ml of alpha-synuclein over 90 minutes, which may be representative of localised 
rises in alpha-synuclein potentially occurring around aggregates, or following cellular 
disruptions such as the death or lysis of neurones.  
 
At the end of the period of alpha-synuclein incubation (90 minutes), all plates were placed on 
ice and ~70-90ul of ice cold PBS was added to the well, followed by centrifugation at 350g for 
5 min, discarding of the supernatant and re-suspension in 180µl of ice cold PBS. The cells were 
then transferred to a 96 well V bottomed plate on ice. This was centrifuged at 350g for 5 min 
and the supernatant was discarded. The remaining cells were washed in FACS buffer and re-
suspended in 100µl of 2% PFA to fix the cells. Following incubation for 15-20 minutes, the 
samples were washed twice, re-suspended in FACS buffer and analysed using flow cytometry.  
 
Flow cytometry 
Flow cytometry was performed on the endocytosis assay samples using the BD LSR Fortessa 
machine and all monocyte events were recorded.  Data was processed using Flow Jo software, 
version 10. The total monocyte percentage positive uptake and MFI ratio values for uptake 






Uptake assays in serum medium 
The uptake assays described above were also performed simultaneously with the participant’s 
autologous serum, instead of RPMI and 10% FCS. Serum was isolated from blood as described 
in the Methods section. The extracted serum was kept at 4ºC until use on the same day. 
 
Microscopy 
A subset of the monocyte post uptake samples was used for microscopy. A proportion of the 
fixed monocyte sample was incubated with the nuclear staining Hoechst dye (Thermofisher 
Scientific) (1:1000) for 30 minutes and then washed with PBS. The cells were re-suspended in 
PBS and smeared onto a glass slide and air dried with protection from light. A glass cover slip 
was applied onto the slide with FluorSaveTM reagent solution. Fluorescent microscopy was 
performed using the Leica DM6000 B microscope, using the blue channel (A4 filter cube) for 
Hoechst and the green channel (L5 filter cube) for fluorescent alpha-synuclein-488. 
 
1.5 Monocyte alpha-synuclein secretion assays 
Monocyte culture 
Separated monocytes were resuspended in RPMI and 10% FCS at a concentration of 1x106 
cells per ml. 1x106 cells were added per well into a 24 well culture plate with and without 
lipopolysaccharide (LPS)(Sigma) (1ng/ml). The cells were cultured for 24 hours at 37ºC and 
5% CO2. At 24 hours, the contents of each well were removed and centrifuged at 350g for 5 





1.6 Monocyte Lysates 
Lysis protocol 
Available separated monocytes were homogenized in a solution containing Tris-buffered saline 
(TBS), 1% Triton X100 (Sigma T8787), Complete protease inhibitor (Roche 04693132001), 
extraction buffer (AbCam ab193970), and enhancer (AbCam ab193971) on ice for 30 minutes. 
The resulting solution was centrifuged at 15,000rcf at 4ºC for 20 minutes. The supernatant was 
removed and assayed for protein concentration.  
Bicinchoninic acid (BCA) assay 
Protein concentration of the lysates was determined according to the manufacturer’s 
instructions (Pierce 23225). Briefly, 50 parts of Reagent A was mixed with 1 part of Reagent 
B and appropriate volumes of the mixture were mixed with a protein sample. The resulting 
solution was incubated at 37ºC for 30 minutes and absorption was measured using the 
Nanodrop reader. The protein concentration was calculated using a standard curve of protein 
concentration versus absorbance for the BCA assay.  
 
Western Blots 
Western blot protocol 
Monocyte lysate samples were mixed with 0.1M dithiothreitol (DTT) and 4X lithium dodecyl 
sulphate (LDS) at the appropriate volumes and boiled at 70ºC for 10 minutes followed by 
centrifugation at 13,000rpm for 5 minutes to remove air bubbles. The samples were then loaded 
onto the wells of a NuPAGE 10% BIS-TRIS gel (Thermofisher) in 1X 3-(N-morpholino) 
propanesulphonic acid (MOPS) running buffer (Thermofisher NP0001), together with the 
protein ladder. The gel was run at 85V for 2 hours, 10 minutes and then transferred onto the 
membrane in 1X Transfer buffer (Thermofisher NP0006)+ 20% methanol.  
 
The membrane was blocked with 5% bovine serum albumin (BSA) or 5% milk in TBS+Tween 
20 (Sigma P9416) (TBST) for 1 hour at room temperature, on a shaker. The primary antibody 
(alpha-synuclein Syn42 (610786, Mouse mAb, BD Bioscience) was added in blocking buffer 
at the appropriate dilution (alpha-synuclein 1 in 2000) and left overnight at 4ºC on a shaker. 
On the following day, the primary antibody was washed off 3 x 10 minutes in TBST. The 
horseradish peroxidase (HRP) conjugated secondary antibody (Sigma A9044) was added in 
blocking buffer (1 in 5000), followed by incubation for 1 hour at room temperature on a shaker 
and thorough washing in TBST.  
 
The blot was visualised using the SuperSignalTM kit (Thermofisher). The membrane was placed 
on top of sealer plastic and a mixture of peroxidase and enhancer was added at a 1:1 ratio on 
to its surface. This was incubated in the dark for 5 minutes, followed by development of the 
signal using the UVI TECH Alliance machine.  
Following the first staining and visualisation, the membrane was stripped by incubation in 
Stripping buffer (15g/L glycine (Sigma G8898), 1g/L sodium dodecyl sulphate (Sigma 75746) 
and 1% v/v Tween 20) for two 30-minute periods, followed by washing in TBST. The 
membrane was then stained with the caspase-1 antibody (D7F10, Rabbit mAb, Cell Signalling 
Technology 1/1000; secondary Sigma AP307P, 1/5000) following the same procedure. 
Subsequently the membrane was stripped again and stained for β-actin (sc-47778, Mouse 
mAB, Santa Cruz) as the loading control.  
The intensity of the appropriate visible bands for both alpha-synuclein and caspase-1 were 




2. Assay Optimisation 
2.1 Monocyte fluorescent alpha-synuclein uptake assay 
The fluorescent alpha-synuclein used (alpha-synuclein (1-140) HiLyteTM Fluor 488) was found 
to contain 0.75 EU/μl of endotoxin contamination (Lonza Bioscience) due to the manufacturing 
process. Previous studies have shown that this fluorescence tagged alpha-synuclein product has 
similar aggregation properties to untagged alpha-synuclein (Anderson and Webb, 2011), but it 
is possible that the presence of endotoxin may influence certain processes such as fibril 
formation (Kim et al., 2016). However, the same alpha-synuclein product and conditions were 
used for all patient and control assays in this study.   
 
Preparatory assays were performed using young control monocytes to optimise the 
concentration of fluorescent alpha-synuclein used and the time course of the experiment 
(Figures A.2, A.3, A.4). Fluorescent alpha-synuclein concentrations of 100ng/ml, 1000ng/ml 
and 10,000ng/ml were trialled at time points of 15, 30, 60 and 90 minutes. As the intention was 
to minimise the time period of the uptake assays, time points beyond 90 minutes were not 
tested. A concentration of 10,000ng/ml at the 90-minute time point produced sufficiently 






Figure A.2 - Flow cytometry gating strategy for monocyte alpha-synuclein-HiLyte-Fluor-
488 uptake. Monocyte gate extended upwards to include positive monocytes, which may have 
increased side scatter. Dividing gate on histogram based on position of 4ºC sample. FSC-
A=Forward scatter –Area; FSC-W = Forward scatter-width; SSC-A= Side scatter-Area 
Figure A.3 – Time course of fluorescent alpha-synuclein-488 uptake.  Alpha-synuclein 
concentration used - 10ng/µl (10,000ng/ml). Subsequent assays were performed at 90 minutes 
throughout the study. % positive uptake is based on 4ºC sample.  
 
Figure A.4 - Titration of alpha-synuclein concentration. Examples of uptake at 90-minute 
time point at concentrations of 100ng/ml, 1000ng/ml and 10,000ng/ml. % positive uptake is 
based on 4ºC sample.  
The outcomes measured in these fluorescent alpha-synuclein assays included the percentage of 
monocytes which had taken up alpha-synuclein compared to the 4ºC sample (Test sample % 
positive - 4ºC sample % positive) and the MFI ratio of total monocytes (Test sample total 









3. Supplementary Results 
3.1 Monocyte subtypes analysis 
The Parkinson’s disease (PD)-Control differences for each marker in each subtype (Figures 
A.5, A.6, A.7) showed overall similar trends to that seen in total monocytes (Figure 2). 
However, the numbers of captured Intermediate (CD14high/CD16positive) and Non-Classical 
(CD14low/CD16high) monocytes per individual were considered too low for sufficiently 
robust analysis and conclusions to be made in this study.  
 
 
Figure A.5 - Classical monocyte marker expression in Parkinson’s disease cases versus 
paired controls; overall and within risk groups.  Graphs showing Classical monocyte MFI 
(Median Fluorescence Intensity) ratios (Test/Isotype) ((A), (C), (E), (G)) and percentage 
Classical monocytes positive ((B), (D), (F), (H)). (Parkinson’s disease=red; Controls=yellow). 
**significance withstood Bonferroni correction for multiple testing within the relevant 
category.  
 
Figure A.6 - Intermediate monocyte marker expression in Parkinson’s disease cases versus 
paired controls; overall and within risk groups.  Graphs showing Intermediate monocyte MFI 
(Median Fluorescence Intensity) ratios (Test/Isotype) ((A), (C), (E), (G)) and percentage 
Intermediate monocytes positive ((B), (D), (F), (H)). (Parkinson’s disease=red; 
Controls=yellow). **significance withstood Bonferroni correction for multiple testing within 
the relevant category.  
 
Figure A.7 – Non-Classical monocyte marker expression in Parkinson’s disease cases versus 
paired controls; overall and within risk groups.  Graphs showing Non-Classical monocyte 
MFI (Median Fluorescence Intensity) ratios (Test/Isotype) ((A), (C), (E), (G)) and percentage 
Non-Classical monocytes positive ((B), (D), (F), (H)). (Parkinson’s disease=red; 
Controls=yellow). **significance withstood Bonferroni correction for multiple testing within 
the relevant category.  
3.2 Monocyte markers and associations with clinical and comorbidity variables 
Variable 




Significance 95% Confidence Interval for B 
Lower Upper 
Total monocyte HLA-DR - 0.308 0.022* -0.567 -0.048 
Age    0.608 0.084 -0.086 1.301 
Disease duration - 1.679 0.359 -5.363 2.005 
Levodopa equivalent dose   0.011 0.133 -0.004 0.026 
CIRS total score - 0.902 0.285 -2.594 0.789 
(ACE-R score)    
Total monocyte HLA-DR  0.216 0.012* 0.052 0.380 
Age  -0.222 0.314 -0.666 0.221 
Disease duration -0.554 0.640 -2.954 1.846 
Levodopa equivalent dose  0.007 0.163 -0.003 0.016 
CIRS total score  0.874 0.102 -0.187 1.935 
Years of Education  0.431 0.196 -0.236 1.098 
(Semantic Fluency)    
Total monocyte HLA-DR 0.227 0.003* 0.086 0.367 
Age  -0.233 0.216 -0.609 0.144 
Disease duration 0.894 0.381 -1.162 2.949 
Levodopa equivalent dose 0.004 0.328 -0.004 0.012 
CIRS total score 0.548 0.219 -0.344 1.440 
Years of Education 0.331 0.244 -0.238 0.901 
Table A.2 – Monocyte HLA-DR and clinical data - Results of Linear Regression Analyses 
with MDS-UPDRS motor score, ACE-R score and Semantic Fluency scores as the dependent 
variables. CIRS – Cumulative Illness Rating Scale. *p<0.05 
 
3.3 Serum assay results 
Serum MSD Assays 
Pro-inflammatory cytokine panel, CRP and alpha-synuclein assays 
Serum samples from visit 1, 2 and 3 were used for these assays and equivalent samples from 
each patient and control pair were analysed within the same experiment. The proteins for which 
>75% of the samples produced a measurable result across visits (IFN-γ, IL-2, IL-6, IL-8, IL-
10, TNF-α, CRP and alpha-synuclein) were included in the analysis.  
The average co-efficient of variance for all the assays repeated across the three visits was <1.0. 
Reliability analysis was performed to calculate the Intraclass correlation coefficient (ICC) 
estimates and their 95% confidence intervals based on a mean-rating (k=3), absolute-
agreement, 2-way mixed-effects model (Koo and Li, 2016). The ICCs for each assay indicated 
that there was a degree of variability in the results from the three visits (Table A.3). Therefore, 












95% Confidence Interval 
Lower Upper 
Serum IFN-γ 0.479 0.201 0.672 
Serum IL-2 0.890 0.827 0.933 
Serum IL-6 0.442 0.155 0.643 
Serum IL-8 0.754 0.635 0.839 
Serum IL-10 0.639 0.453 0.769 
Serum TNFα 0.777 0.670 0.853 
Serum CRP 0.425 0.129 0.632 
Serum Alpha-synuclein 0.469 0.196 0.660 
 
 
Table A.3 -Reliability analysis of serum assays - Table showing the Intraclass Correlation 
Coefficients (ICCs) of the serum markers measured at three time points. ICC approaching 1.0 












Paired Controls p  
Number (n) 
All 41 41 
 HR 23 23 
LR 18 18 
IFN-γ 
All 6.86 (3.66) 8.63 (4.24)  0.0873 
HR 6.46 (3.32) 9.32 (4.70)  0.0484* 
LR 7.34 (4.07) 7.75 (3.49)  0.7660 
IL-2 
All 0.16 (0.06) 0.17 (0.08) 0.0785 
HR 0.15 (0.06) 0.20 (0.10) 0.0576 
LR 0.15 (0.08) 0.15 (0.07) 0.8653 
IL-6 
All 0.76 (0.42) 0.67 (0.24) 0.1366 
HR 0.86 (0.52) 0.67 (0.25) 0.1069 
LR 0.65 (0.20) 0.66 (0.24) 0.8525 
IL-8 
All 9.84 (2.84) 10.68 (3.24) 0.2604 
HR 9.30 (2.42) 10.24 (1.86) 0.1929 
LR 10.54 (3.23) 11.23 (4.42) 0.6353 
IL-10 
All 0.24 (0.12) 0.26 (0.13)  0.5099 
HR 0.26 (0.13) 0.26 (0.10)  0.8987 
LR 0.22 (0.09) 0.25 (0.16)  0.3692 
TNF-α 
All 2.48 (0.62) 2.66 (0.56) 0.1642 
HR 2.61 (0.67) 2.71 (0.39) 0.5336 



















All 18,654.48 (6707.89) 33,112.36 (9552.62) <0.0001** 
HR 18,719.03 (6665.36) 33,629.46 (9084.03) <0.0001** 
LR 18,567.14 (6969.64) 32,451.61 (10,348.80) 0.0001** 
 
 
Table A.4 - Summary of serum MSD assay results (cytokines, CRP and alpha-synuclein). All 
values indicated are the mean concentration (standard deviation) in pg/ml. Significance (p) 
indicated is that from paired analysis (parametric paired t-tests - IL-2, IL-6, IL-8, TNF-α; non-
parametric Wilcoxon-matched pairs tests – IFN-γ, IL-10, CRP, alpha-synuclein).  
*p<0.05; ** remains significant following correction for multiple testing over all analysed 




3.4 Serum markers and associations with clinical and comorbidity variables 
 
Figure A.8 – Serum alpha-synuclein and motor function - Scatter plot of serum alpha-




Significance 95% Confidence Interval 
for B 
Lower Upper 
Serum alpha-synuclein -0.001 0.051 -0.001 0.000 
Age 0.526 0.124 -0.152 1.204 
Disease duration -1.214 0.502 -4.852 2.424 
Levodopa equivalent dose 0.005 0.470 -0.009 0.020 
CIRS total score -0.617 0.467 -2.323 1.089 
 
Table A.5- Serum alpha-synuclein and clinical data. Linear Regression Analysis with UPDRS 
motor score as the dependent variable. CIRS – Cumulative Illness Rating Scale.  
 
 
3.5 Principal Component Analysis (PCA) 
A PCA was run using all participant data on all monocyte markers and the serum markers with 
uncorrected significant results on overall PD-Control paired analysis. Where more than one 
measure relating to a factor was significant (e.g. % positive and MFI ratio), the most significant 
measure for each factor was used for the PCA. Thus, the variables included in the PCA were   
-: classical monocyte %, monocyte TREM2 MFI ratio, monocyte HLA-DR MFI ratio, TLR2+ 
monocyte %, TLR4+ monocyte %, serum caspase-1, serum alpha-synuclein, serum endotoxin. 
The suitability of PCA was assessed prior to analysis. Variables with the lowest Kaiser-Meyer-
Olkin (KMO) measures were removed until all the individual KMO measures were greater than 
0.55, resulting in the exclusion of TLR4 and HLA-DR from the PCA. The overall KMO 
measure for Sampling Adequacy was 0.627. Bartlett's test of sphericity was statistically 
significant (p=0.001), indicating that the data was likely factorable.  
 
PCA revealed two components that had eigenvalues greater than one and which explained 
32.48% and 19.48% of the total variance, respectively. One further component had an 
eigenvalue > 0.94, explaining a further 15.67% of the variance and visual inspection of the 
scree plot indicated that three components should be retained. The three-component solution 
cumulatively explained 67.64% of the total variance. A Varimax rotation with Kaiser 
normalization was employed to aid interpretability (Table 2).  
 
 
3.6 Endotoxin and TREM2 
 
Figure A.9 - Serum endotoxin and soluble TREM2 - Graph demonstrating a positive 





Significance 95% Confidence Interval for 
B 
Lower Upper 
Serum Endotoxin 123.59 0.005 39.80 207.38 
Total Monocyte TREM2 -2.52 0.660 -13.96 8.90 
Age 15.38 0.083 -2.06 32.84 
 
Table A.6 - Serum endotoxin and soluble TREM2 - Multiple linear regression analysis with 





















Figure A.10 - Monocyte Lysates – (A) and (B) Western blots of monocyte lysates for alpha-
synuclein (A) and caspase-1 (B), with beta-actin loading control. P=Patient; C=Control. 
(C) and (D) Monocyte lysate alpha-synuclein (C) and caspase-1 (D) content as a ratio of 
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